MediWound Ltd.

NASDAQ:MDWD

Biotechnology

Healthcare
$13.61 -0.60%

-$0.09 today

Market cap
$175.71M
Beta
0.15
P/E (TTM)
-7.0
EPS (TTM)
-$2.03
52W Low $13.54High $21.26

Volume 0.17M

Average 0.09M

MDWD Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

MediWound Ltd.NASDAQ: MDWD

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow grows, but more slowly than its trailing trend

Q1 FY2026 financing cash flow of $421K (cash outflow) rose 16.3% year over year, behind the +54.5% change in trailing-twelve-month financing cash flow. Sequentially, it fell 73.3% from the prior quarter. Over 3 fiscal years it compounded at -6.1% a year.

Context

  • Financing cash flow amounted to 174.7% of revenue in FY2025, up 78.8 pp from a year earlier.
  • Financing cash flow increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +16.3% toward the trailing-twelve-month pace of +54.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$421K-73.3% QoQ
Last fiscal yearDec 2025
$29.62M+52.7% YoY
LTMMar 2026
$30.48M+54.5% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+16.3%——
1 year+52.7%——
3-year CAGR-6.1%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
29.62M USD
Year-over-year change
+52.7%

Financing Cash Flow vs competitors

How MDWD compares with its peers on the latest reported figures

  • Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +54.5% is the 6th highest of 9, against a peer median of +88.8%.
  • Financing cash flow amounts to 210.5% of revenue for MDWD, versus a peer median of 633.5%.
MDWD Competitors
Financing Cash Flow for MDWD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IVAInventiva S.A.FY2025€232M EUR+59.4%+84.0%5175.1%
IVVDInvivyd, Inc.LTM Mar 2026$215.52M USD+89700.8%+652.5%385.8%
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026$122.33M USD+380.3%+92.7%—
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026$117.69M USD+118.3%+53.0%—
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$94.16M USD+226.3%-5.1%287.7%
TARAProtara Therapeutics, Inc.LTM Mar 2026$82.13M USD-42.0%——
MDWDMediWound Ltd.LTM Mar 2026$30.48M USD+54.5%-6.1%210.5%
NTHINeonc Technologies Holdings, Inc.LTM Mar 2026$16.91M USD———
RNACCartesian Therapeutics, Inc.LTM Mar 2026$15.64M USD-86.7%—881.2%
AARDAardvark Therapeutics, Inc. Common StockLTM Mar 2026$378K USD-99.8%+634.8%—
Peer median (excluding MDWD) —+88.8%+88.3%633.5%

Competitors are the stored peer set for MDWD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(13.55M)(19.6M)(6.72M)(30.22M)(23.88M)
Depreciation & Amortization1.24M1.27M1.3M1.48M1.71M
Deferred Income Tax(124K)0000
Stock-Based Compensation1.67M1.95M1.94M3.14M3.11M
Change in Working Capital162K(7.24M)2.34M1.27M4.77M
Accounts Receivables929K(7.58M)4.76M(1.02M)4.88M
Inventory257K(721K)(906K)187K(1.36M)
Accounts Payables1.72M414K(594K)406K2.35M
Other Working Capital(2.75M)645K(928K)1.7M(1.1M)
Other Non-Cash Items1.69M11.74M(9.33M)10.71M(236K)
Operating Cash Flow(8.92M)(11.89M)(10.47M)(13.62M)(14.53M)
Capital Expenditures(489K)(555K)(6.46M)(6.27M)(5.51M)
Acquisitions (Net)00000
Purchases of Investments0000(14.04M)
Sales of Investments4M0000
Other Investing Activities35K74K(27.86M)(2.12M)0
Investing Cash Flow3.55M(481K)(34.32M)(8.4M)(19.54M)
Debt Repayment000(928K)0
Common Stock Issued3K38.38M24.91M22.17M31.05M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(1.05M)(2.62M)(1.99M)(1.84M)(1.43M)
Financing Cash Flow(1.05M)35.76M22.92M19.39M29.62M
Effect of Forex Changes88K(549K)(160K)(84K)95K
Net Change in Cash(6.33M)22.85M(22.03M)(2.71M)(4.36M)
Free Cash Flow(9.41M)(12.44M)(16.93M)(19.9M)(20.04M)

MediWound Ltd.

NASDAQ:MDWD

Intrinsic Alpha fair value

Locked

Current Price

$13.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.